From Seekingalpha · Stephen Ayers · · 50s
Regeneron Stock Downgraded to Hold
Regeneron's stock now priced at $735 near DCF value after rating downgrade.
In brief
Regeneron's stock now priced at $735 near DCF value after rating downgrade. Regeneron Pharmaceuticals stock is downgraded to 'Hold' as its price aligns with discounted cash flow valuation. Originally reported by Seekingalpha.
Rating Downgrade
Regeneron Pharmaceuticals is downgraded to 'Hold' as its stock now appears appropriately priced at $735, near DCF value.
DUPIXENT Growth
DUPIXENT continues to outperform, driving a 17% revenue jump and providing a strong margin of safety.
EYLEA HD Durability
EYLEA HD's durability offsets legacy declines, aided by extended dosing intervals and delayed biosimilar competition until 2027.
R&D Setbacks
R&D setbacks, notably the fianlimab trial failure, weaken the growth thesis; near-term catalysts include Q3 results and the cemdisiran decision.
Analyst Background
Stephen Ayers has a background as a RN and completed an MBA, analyzing healthcare stocks through clinical data and DCF modeling.
The headline
Regeneron Pharmaceuticals stock is downgraded to 'Hold' as its price aligns with discounted cash flow valuation.
